Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BRIGHT (Breast Cancer Resilience Intervention for Growth, Hope and Thriving): Co-Designing and Feasibility Testing a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors in Ireland

NCT07930715 is registered in ClinicalTrials.gov with University College Dublin as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07930715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
BRIGHT (Breast Cancer Resilience Intervention for Growth, Hope and Thriving): Co-Designing and Feasibility Testing a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors in Ireland
Lead sponsor
University College Dublin
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 31, 2029
Completion date
September 30, 2030
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cancer survivorship

Arms

As registered; 2 arms.

  • BRIGHT Resilience Intervention ExperimentalBRIGHT Resilience Intervention

    Participants attend the 8-week culturally tailored BRIGHT resilience intervention: weekly 90-minute

  • Enhanced Usual Care Active comparatorBRIGHT Survivorship Resource Booklet

    Participants receive standard oncology survivorship care plus the BRIGHT Survivorship Resource Booklet. They are offered the BRIGHT resilience intervention after the 3-month follow-up (waitlist crossover).

Primary endpoints

Registered primary outcome measures; 5 primary.

  • Recruitment Rate From start to end of recruitment, up to 6 months

    Number of participants randomised per site per month. Progression target: at least 4 participants per site per month.

  • Retention 3 months after the end of the intervention

    Percentage of randomised participants who complete the 3-month follow-up questionnaires. Progression target: at least 80%.

  • Session Attendance During the 8-week intervention

    Percentage of the 8 intervention sessions attended by participants in the BRIGHT arm, from attendance records. Progression target: at least 75% session completion.

  • Intervention Fidelity During the 8-week intervention

    Percentage of planned session components delivered as intended, assessed using facilitator session checklists and independent review of a sample of recorded sessions. Progression target: at least 85%.

  • Acceptability Week 8 (end of the intervention)

    Participant satisfaction with the intervention, measured using a questionnaire based on the Theoretical Framework of Acceptability, and explored in interviews with 15 to 20 participants and facilitators.

Lead sponsor's other trials

University College Dublin, most recent start first.

Similar trials

Same condition (Breast Neoplasms) and phase, most recent start first.